A complete application in a minute
Tailored resume and cover letter, ready to send.
Replimune is seeking a Quality Control Laboratory Technician in Abingdon, UK to support daily laboratory operations and reagent management. The role involves tissue culture prep, equipment checks, sample receipt, and reagent ordering within SOPs.
Ideal candidates will have GCSEs in science subjects, strong time management, and proficiency with MS Word and Excel. A collaborative, detail-oriented mindset is essential for maintaining quality and safety in a fast-paced lab.
Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response, boldly transforming cancer care because patient’s lives depend on it.
United: We Collaborate for a Common Goal. Audacious: We Are Bold. Dedicated: We Give Our Full Commitment. Candid: We Are Honest With Each Other.
People are at the center of everything we do, and when it comes to our employees, we make it personal. With a deep sense of purpose, a strong and evolving culture, a competitive and forward-looking total rewards program, everyone at Replimune has a unique opportunity to impact on the lives of patients, caregivers and themselves.
Join us, as we reshape the future.
The Quality Control (QC) Laboratory Technician will perform various laboratory- related activities such as reagent preparation, tissue culture, equipment maintenance, sample receipt and disposal, maintenance of consumable and reagent inventory, ordering reagents and preparing reagents following relevant standard operating procedure (SOP). After adequate experience and training the role can also involve performing some simple QC testing using established test methods.
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
We are an Equal Opportunity Employer.